PRTA (Prothena Corp) Future Price to Earnings
The daily price chart for Prothena Corporation (PRTA) illustrates the dynamics of a company with a metric of 0.00. The business relies on outsourcing drug manufacturing and conducting tests through contractors, maintaining the scientific team's agility in the fight against amyloidosis. While management possesses significant experience, a strategy based on binary trial outcomes renders shareholder confidence volatile, requiring a high degree of patience.
Summary analytical data breakdowns for prothena.com (PRTA)
- stock value and consensus price forecast:
- business market valuation indicators:
- balance sheet equity data:
- debt level and financial liquidity data:
- financial results and valuation multiples details:
PRTA - Net Income|Expected Profit Prothena Corporation|PRTA - Market Cap to Earnings|Future Price to Earnings Prothena Corp|PRTA - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prothena Corporation PLC|PRTA - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months Prothena|PRTA - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months prothena.com|PRTA - Earnings per share increase in current year|Earnings growth forecast for next year Prothena Corporation
Summary company analytics:Prothena Corporation PLC
Forward P/E determines the stock value relative to expected net income, serving as an indicator of investment attractiveness. For Prothena Corporation (PRTA), the company's expected price-to-earnings multiple reflects the market rate for the future monopolization of the neurodegenerative disease therapy market. The curve's dynamics allow for an assessment of asset revaluation without the influence of one-off reports. A decrease in this metric confirms the fundamental stability of the business. However, excessive optimism remains risky until the success of clinical trials is confirmed.
Analysis of competing companies
Future Price to Earnings Biogen (BIIB)|NBIX (Neurocrine) - Future Price to Earnings Multiple|Future Price to Earnings Regencell RGC|Axsome Corp (AXSM) - Projected Price to Earnings Ratio|ACAD: Projected Price to Earnings|xenon-pharma.com - Market Cap to Future Earnings Ratio|VKTX: Forward P/E Multiple|Supernus Pharmaceuticals, Inc. - Future Price to Earnings Multiple|CPRX (Catalyst Pharmaceuticals Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Denali Corp DNLI|Future Price to Earnings Harmony Biosciences (HRMY)|biohavenpharma.com - Price to Future Earnings Ratio|Forward P/E Multiple AMLX (Amylyx Pharmaceuticals, Inc.)|Forward P/E Multiple Trevi Therapeutics Inc TRVI|PRAX: Projected Price to Earnings|Future Price to Earnings Multiple AVXL (Anavex Life Sciences Corp)|CBLL: Forward P/E Multiple|Projected Price to Earnings Alector|Future Price to Earnings Annexon|Projected Price to Earnings Ratio Omeros Corp. OMER|Future Price to Earnings Neurogene Corp (NGNE)|ACIU (AC Immune Inc) - Future Price to Earnings Multiple|Future Price to Earnings Voyager Therapeutics VYGR|NMRA (neumoratx.com) - Price to Expected Earnings Ratio|SCLX - Future Price to Earnings|Projected Price to Earnings Ratio Tevogen Bio Holdings Inc.|alphacognition.com (ACOG) - Future Price to Earnings|Cognition Therapeutics Inc. - Future Price to Earnings Multiple|IKT (Inhibikase Therapeutics) - Forward P/E Multiple|Forward P/E Multiple cassavasciences.com|Projected Price to Earnings ASRT (Assertio Holdings, Inc.)|Market Cap to Future Earnings Ratio COYA|Forward P/E Multiple VTGN (Vistagen)|Market Cap to Projected Earnings Ovid Therapeutics Inc (OVID)|ABOS - Future Price to Earnings|Projected Price to Earnings Ratio cervomed.com|alteritytherapeutics.com (ATHE) - Future Price to Earnings|Price to Future Earnings Ratio CLNN|Future Price to Earnings PepGen Inc|Jupiter Neurosciences, Inc. - Price to Expected Earnings Ratio|Future Price to Earnings Relmada Therapeutics (RLMD)|ANVS (annovisbio.com) - Future Price to Earnings Multiple|Grace Therapeutics - Projected Price to Earnings|Market Cap to Future Earnings Ratio AIFF (Firefly Neuroscience, Inc.)|ANEW Medical, Inc. - Forward P/E Multiple|NRSN - Forward P/E Multiple|Reviva Pharmaceuticals (RVPH) - Future Price to Earnings|Price to Future Earnings Ratio MTVA|NRXS (NeurAxis) - Forward P/E Multiple|Projected Price to Earnings Ratio Helius Medical Technologies Inc. HSDT|Projected Price to Earnings PASG (Passage Bio, Inc.)|Forward P/E Multiple bionomics.com.au (NEUP)|Future Price to Earnings Minerva Neurosciences NERV|Future Price to Earnings Multiple ATHA|ADXN - Future Price to Earnings|Projected Price to Earnings Ratio Alzamend Neuro, Inc.|cyclerion.com (CYCN) - Future Price to Earnings|Price to Expected Earnings Ratio PTIX (Protagenic Therapeutics, Inc.)|Future Price to Earnings Pasithea Therapeutics Corp|CRGT: Future Price to Earnings Multiple|Future Price to Earnings Avenue Therapeutics, Inc. (ATXI)|BCLI - Projected Price to Earnings Ratio|Cara Therapeutics, Inc - Projected Price to Earnings|Market Cap to Future Earnings Ratio CHRO (Chromocell)|Eliem - Forward P/E Multiple|Future Price to Earnings Multiple ITCI (Intra-Cellular Therapies)|LBPH: Forward P/E Multiple|Projected Price to Earnings Ratio Marinus Pharmaceuticals Inc (MRNS)|Future Price to Earnings NKGen|Price to Future Earnings Ratio NRBO (NeuroBo Pharma)|Forward P/E Multiple SAGE|Forward P/E Multiple synaptogen.com (SNPX)|Trevena - Projected Price to Earnings|Future Price to Earnings Multiple VIGL|Anew Medical - Forward P/E Multiple|Cerevel Corp (CERE) - Projected Price to Earnings
